Extrapulmonary manifestations of COVID-19

@article{Gupta2020ExtrapulmonaryMO,
  title={Extrapulmonary manifestations of COVID-19},
  author={Aakriti Gupta and Mahesh V. Madhavan and Kartik Sehgal and Nandini Nair and Shiwani Mahajan and Tejasav S. Sehrawat and Behnood Bikdeli and Neha Ahluwalia and John Ausiello and Elaine Y. Wan and Daniel E. Freedberg and Ajay J. Kirtane and Sahil A. Parikh and Mathew S. Maurer and Anna S Nordvig and Domenico Accili and Joan M Bathon and Sumit Mohan and Kenneth A. Bauer and Martin B. Leon and Harlan M. Krumholz and Nir Uriel and Mandeep R. Mehra and Mitchell S. V. Elkind and Gregg W. Stone and Allan Schwartz and David D. Ho and John P. Bilezikian and Donald W. Landry},
  journal={Nature Medicine},
  year={2020},
  volume={26},
  pages={1017-1032}
}
Although COVID-19 is most well known for causing substantial respiratory pathology, it can also result in several extrapulmonary manifestations. These conditions include thrombotic complications, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastrointestinal symptoms, hepatocellular injury, hyperglycemia and ketosis, neurologic illnesses, ocular symptoms, and dermatologic complications. Given that ACE2, the entry receptor for the causative coronavirus… 

Extrapulmonary Clinical Manifestations in COVID-19 Patients

TLDR
This review outlines the extrapulmonary organ–specific complications and their pathophysiology and epidemiology of COVID-19 patients and outlines the mechanisms leading to multiple organ failure.

Extra-Pulmonary Complications in SARS-CoV-2 Infection: A Comprehensive Multi Organ-System Review

TLDR
Understanding the broad spectrum of atypical extra-pulmonary manifestations of COVID-19 should increase disease surveillance, restrict transmission, and most importantly prevent multiple organ-system complications.

Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19

TLDR
A holistic approach should be adopted by healthcare professionals while treating COVID-19 patients with a history of neurodegenerative disorders, neuropsychological complications, or any other neuro-compromised conditions, as well as the possible mechanisms of amelioration.

COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication

TLDR
Cardiovascular involvement in the COVID-19 pandemic is reviewed with respect to clinical features, pathogenesis, long-term effects, and the adverse effects of treatments and vaccines based on the latest evidence.

Imaging spectrum of abdominal manifestations of COVID-19

TLDR
An overview of the various gastrointestinal imaging manifestations that can be encountered in patients with COVID-19, with an emphasis on early diagnosis of the disease as well as treatment related complications is provided.

COVID-19 and cerebrovascular diseases: a comprehensive overview

TLDR
This narrative review sought to present the possible pathophysiological mechanisms linking COVID-19 and cerebrovascular disease, describe the stroke syndromes and their prognosis and discuss several clinical, radiological, and laboratory characteristics that may aid in the prompt recognition of cerebroVascular disease during CO VID-19.

Therapeutic challenges of extrapulmonary dual organ system involvement in COVID‑19: A case report

TLDR
A 64-year-old patient with CoVID‑19 with marked extrapulmonary manifestations in the setting of strong positive reactions with cycle threshold values of reverse transcription polymerase chain reaction is described, with a case study of a patient who eventually succumbed to the disease after 6 days of hospitalization.

COVID-19 and hypopituitarism

TLDR
This review will discuss hypopituitarism as a condition that might have a bidirectional relationship with CO VID-19 due to the frequent presence of metabolic comorbidities, to the direct or indirect pituitary damage or being per se a potential risk factor for COVID-19.

Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations

Vasculopathy in COVID-19

TLDR
A conceptual framework describing how SARS-CoV-2 infection affects endothelial inflammation, prothrombotic transformation, and barrier dysfunction will provide a context for interpreting new information as it arises addressing the vascular complications of COVID-19.
...

References

SHOWING 1-10 OF 278 REFERENCES

COVID-19 and its implications for thrombosis and anticoagulation

TLDR
COVID-19–associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagULopathy or DIC.

Collapsing glomerulopathy in a COVID-19 patient

COVID-19 and the liver: little cause for concern

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

TLDR
Novel dosing approaches are described for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithsombotic drugs in the absence of confirmed thrombosis.

Hematological findings and complications of COVID‐19

TLDR
COVID‐19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended.

COVID-19 Presenting as Acute Hepatitis

TLDR
The first case of COVID-19 presenting as acute, nonicteric hepatitis is reported, with a 59-year-old woman admitted because of the concern of rising liver tests in a patient with human immunodeficiency virus disease.
...